Lab Team

David F Jarrard, MD (Principal investigator) 

jarrard@urology.wisc.edu
MD, University of Virginia School of Medicine, Charlottesville, VA.
Junior Residency in General Surgery, University of Chicago, Chicago, IL.
Residency in Urology, University of Chicago, Chicago, IL.
Fellow in Urologic Oncology, American Foundation for Urologic Disease, Johns Hopkins University, Baltimore, MD.

Dr. Jarrard a tenured Professor, Vice Chair for the Department of Urology, and Deputy Director at the UW Carbone Cancer Center at the University of Wisconsin. He is a physician-scientist with expertise in clinical urologic cancer management, clinical trials, and translational research. He currently holds the John Livesey Chair in Urologic Oncology and am a member of the Wisconsin Institute for Discovery Epigenetics program. Service on several national committees includes prostate cancer guidelines panels for the National Comprehensive Cancer Network (NCCN) and the American Urological Association (AUA).  National leadership roles have included past-President of the AUA North Central Section, the Society for Basic Urologic Research (SBUR), and Society for Academic Urology (SAU) and co-Chair of the Research, Education, and Conferences Committee (RECCC) for the AUA. He has wide-ranging experience serving as a reviewer and chair.

His clinical work concentrates on the surgical treatment of prostate cancer and improving cancer detection and outcomes. He serves as the urology co-PI on the paradigm-shifting CHAARTED trial of docetaxel and androgen deprivation therapy (ADT) for metastatic HSPC, and on other trials in chemoprevention and advanced prostate cancer management.

Dr. Jarrard is the principle investigator for the University of Wisconsin Prostate Cancer Special Program of Research Excellence (SPORE), a highly competitive grant focused on translating research into new treatments for our patients. Other basic science and translational research interests are supported through the NIH (R01) and the Department of Defense Prostate Cancer Research Program examining epigenetic factors underlying prostate cancer progression and novel approaches to treating advanced disease. This work has led to the development of novel epigenetic and imaging biomarkers in normal tissue. Recent innovations include the recognition that androgen removal, a common treatment in advanced prostate cancer, when combined with agents targeting unique epigenetic and metabolic changes can improve cancer outcomes. He has published numerous chapters, articles, and abstracts in the field of prostate cancer.  Dr. Jarrard has an extensive and enthusiastic history of mentoring graduate, undergraduate, residents, and faculty.

Perform a PubMed search for Dr. Jarrard’s publications